33330 Federal Register / Vol. 65, No. 100 / Tuesday, May 23, 2000 / Notices

This is a one-time survey. The burden

estimate is based on FDA’s experience

with conducting similar surveys.

Dated: May 15, 2000.

William K. Hubbard,

Senior Associate Commissioner for Policy,

Planning, and Legislation.

[FR Doc. 00–12854 Filed 5–22–00; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Food and Drug Administration

Psychopharmacological Drugs

Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

This notice announces a forthcoming

meeting of a public advisory committee

of the Food and Drug Administration

(FDA). The meeting will be open to the

public.

Name of Committee:

Psychopharmacological Drugs Advisory

Committee

General Function of the Committee:

To provide advice and

recommendations to the agency on

FDA’s regulatory issues.

Date and Time: The meeting will be

held on July 19, 2000, 8 a.m. to 5 p.m.

Location: Holiday Inn, Versailles

Ballrooms I, II, and III, 8120 Wisconsin

Ave., Bethesda, MD.

Contact Person: Sandra L. Titus or

LaNise S. Giles, Center for Drug

Evaluation and Research (HFD–21),

5600 Fishers Lane (for express delivery,

5630 Fishers Lane, Rm. 1093) Rockville,

MD 20857, 301–827–7001, or e-mail

Tituss@cder.fda.gov, or FDA Advisory

Committee Information Line, 1–800–

741–8138 (301–443–0572 in the

Washington, DC area) code 12544.

Please call the Information Line for upto-date information on this meeting.

Agenda: The committee will consider

the safety and efficacy of new drug

application (NDA) 20–825, ZeldoxTM

(ziprasidone hydrochloride capsules,

Pfizer, Inc.), proposed for the

management of psychotic disorders.

Procedure: Interested persons may

present data, information, or views,

orally or in writing, on issues pending

before the committee. Written

submissions may be made to the contact

person by July 17, 2000. Oral

presentations from the public will be

scheduled on July 19, 2000, between

approximately 1 p.m. to 2 p.m. Time

allotted for each presentation may be

limited. Those desiring to make formal

oral presentations should notify the

contact person before July 17, 2000, and

submit a brief statement of the general

nature of the evidence or arguments

they wish to present, the names and

addresses of proposed participants, and

an indication of the approximate time

requested to make their presentation.

Notice of this meeting is given under

the Federal Advisory Committee Act (5

U.S.C. app. 2).

Dated: May 11, 2000.

Linda A. Suydam,

Senior Associate Commissioner.

[FR Doc. 00–12855 Filed 5–22–00; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Food and Drug Administration

[FDA 225–00–2000]

Memorandum of Understanding

Between the Food and Drug

Administration, U.S. Department of

Health and Human Services, and the

Food Safety and Inspection Service,

U.S. Department of Agriculture,

Regarding the Listing or Approval of

Food Ingredients and Sources of

Radiation Used in the Production of

Meat and Poultry Products

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

SUMMARY: The Food and Drug

Administration (FDA) is providing

notice of a memorandum of

understanding (MOU) between FDA and

the Food Safety and Inspection Service,

U.S. Department of Agriculture (FSIS).

The purpose of the agreement is to

establish the working relationship to be

followed by FDA and FSIS in

responding to requests for the

sanctioning of the use of food

ingredients and sources of radiation

subject to regulation by FDA and

intended for use in the production of

meat and meat food products.

DATES: The agreement became effective

January 31, 2000.

FOR FURTHER INFORMATION CONTACT:

Arletta M. Beloian, Center for Food

Safety and Applied Nutrition (HFS–

206), Food and Drug Administration,

200 C St. SW., Washington, DC 20204,

202–418–3082.

SUPPLEMENTARY INFORMATION: In

accordance with 21 CFR 20.108(c),

which states that all written agreements

and MOU’s between FDA and others

shall be published in the Federal

Register, the agency is publishing notice

of this MOU.

Dated: May 16, 2000.

William K. Hubbard,

Senior Associate Commissioner for Policy,

Planning, and Legislation.

The MOU is set forth in its entirety as

follows:

BILLING CODE 4160–01–F

Federal Register / Vol. 65, No. 100 / Tuesday, May 23, 2000 / Notices 33331

33332 Federal Register / Vol. 65, No. 100 / Tuesday, May 23, 2000 / Notices

Federal Register / Vol. 65, No. 100 / Tuesday, May 23, 2000 / Notices 33333

33334 Federal Register / Vol. 65, No. 100 / Tuesday, May 23, 2000 / Notices

[FR Doc. 00–12853 Filed 5–22–00; 8:45 am]

BILLING CODE 4160–01–C

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

Proposed Collection; Comment

Request: National Institute of Diabetes

and Digestive and Kidney Diseases

Information Clearinghouse Customer

Satisfaction Survey

SUMMARY: In compliance with the

requirement of section 3506(c)(2)(A) of

the Paperwork Reduction Act of 1995 to

provide opportunity for public comment

on proposed data collection projects; the

National Institute of Diabetes and

Digestive and Kidney Diseases (NIDDK),

the National Institutes of Health (NIH),

will publish periodic summaries of

proposed projects to be submitted to the

Office of Management (OMB) for review

and approval.

Title: NIDDK Information

Clearinghouses Customer Satisfaction

Survey.

NIDDK will conduct a survey to

evaluate the efficiency and effectiveness

of services provided NIDDK’s three

information clearinghouses: National

Diabetes Information Clearinghouse,

National Digestive Diseases Information

Clearinghouse, National Kidney and

Urologic Diseases Information

Clearinghouse. The survey responds to

Executive Order 12862, ‘‘Setting

Customer Service Standards,’’ which

requires agencies and departments to

identify and survey their ‘‘customers to

determine the kind and quality of

service they want and their level of

satisfaction with existing service.’’

Frequency of Response: On occasion.

Affected Public: Individuals or

households; clinics or doctor’s offices.

Type of Respondents: Physicians,

nurses, patients, family.